T-Cell Lymphoma
T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Advertisement
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerFollicular Lymphoma | December 12, 2024
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Andrew MorenoT-Cell Lymphoma | December 10, 2024
Limitations on benefits from immunotherapy in this setting increase clinical interest in this CAR T-cell therapy approach.
Andrew MorenoT-Cell Lymphoma | December 10, 2024
Diagnosis is challenging due to the high variety of origin cell types, clinical manifestations, genetics, and histology.
Andrew MorenoT-Cell Lymphoma | December 9, 2024
Efficacy was evaluated specifically in PTCL and safety in PTCL along with adult T-cell leukemia or lymphoma.
Andrew MorenoT-Cell Lymphoma | November 11, 2024
The study used CRISPR screening to identify susceptibility markers for brentuximab vedotin in CD30-positive PTCLs.
Advertisement
Andrew MorenoT-Cell Lymphoma | November 12, 2024
Consensus clinical practice recommendations regarding use of this potentially curative procedure had previously been absent.
Andrew MorenoT-Cell Lymphoma | November 8, 2024
Recent advances in knowledge about PTCL biology help inform clinical trial design and use of precision therapy.
Andrew MorenoT-Cell Lymphoma | November 13, 2024
Co-authors of a new review article suggest other factors more strongly influence secondary tumor development.
Andrew MorenoT-Cell Lymphoma | November 13, 2024
A single-center study compared the secondary and initial tumors and assessed vector viral integration's role in oncogenesis.
Melissa BadamoT-Cell Lymphoma | October 30, 2024
Six percent of patients with lymphoma or myeloma developed second primary malignancies after CAR T-cell therapy.
Melissa BadamoT-Cell Lymphoma | October 9, 2024
Stefan K. Barta, MD, MS, discusses his recent study on central nervous system relapse in T-cell lymphomas.
Melissa BadamoT-Cell Lymphoma | September 27, 2024
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
Melissa BadamoT-Cell Lymphoma | September 27, 2024
The PETAL Consortium at the Jain Lab integrates AI-informed digital interface as a tool to facilitate clinical decisions.
Andrew MorenoT-Cell Lymphoma | September 6, 2024
Molecular analysis insights have improved clinical evaluation and management decision-making for the different PTCL subtypes.
Andrew MorenoT-Cell Lymphoma | September 6, 2024
A recent commentary makes recommendations to improve development and accelerated regulatory approval of novel agents.
Andrew MorenoT-Cell Lymphoma | September 6, 2024
A trial used consolidation after combination cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide.
Melissa BadamoT-Cell Lymphoma | August 19, 2024
Treatment with the monoclonal antibody 208 alone, and in combination with duvelisib, extended survival.
Andrew MorenoT-Cell Lymphoma | August 8, 2024
Subgroup analysis highlighted chemotherapy, disease type, and transplant factors associated with greater treatment efficacy.
Andrew MorenoT-Cell Lymphoma | August 8, 2024
Most grade 3 or worse adverse events had less occurrence in azacitidine therapy than in standard therapy.
Advertisement
Advertisement
Editorial Board